Antivirals

#Antivirals #Drug development #Drug discovery #Henipavirus #Investment

Millions invested in antiviral medicines for future pandemics 

The partners in the Pandemic Antiviral Discovery (PAD) initiative have announced grants totalling more than $26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.  These grants mark the majority of the first investments to come… Read More

#News

Testing antiviral vaccines in the lab
#Antivirals #Clinical research #Investment #Pandemic prevention

$12 million awarded for the development of antiviral therapies

Three institutions have received a share of $12 million for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.  The money was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID may… Read More

#News

Monkeypox virus
#Antivirals #DNA mutations #Immunology / Virology & Vaccines #Monkeypox #Monkeypox vaccine #Virus mutation

Researchers reveal how monkeypox evolves to evade drugs 

A team of scientists has identified the specific mutations in the monkeypox virus that contribute to its continued infectiousness. Monkeypox has infected more than 77,000 people in more than 100 countries worldwide. Mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and… Read More

#News #Trending News

HIV cell and antibodies
#Antibodies #Antivirals #HIV

Trial results support potential new therapeutic approach to HIV 

Positive study findings for N6LS, an investigational, broadly neutralising antibody (bNAb), could indicate a potential new approach for the treatment of HIV.  ViiV Healthcare, a specialist HIV company owned by GSK, Pfizer and Shionogi, presented positive findings from its Phase IIa proof-of-concept study of N6LS at the… Read More

#News

Bananas
#Antivirals #Genetic engineering #Immunology / Virology & Vaccines #Proteins

Engineered banana lectin could become broad spectrum antiviral 

An international team of scientists have engineered protein banana lectin, or BanLec, to create a new version that can fight off a range of viruses without unwanted side effects.  The genetically engineered version has been called H84T and worked against the viruses that cause AIDS, hepatitis… Read More

#News

Covid patient receiving oxygen
#Antivirals #Clinical trial #Covid-19 #Human trials

POC study proves efficacy of zapnometinib in severe Covid-19

A proof of concept (POC) study has shown the clinical benefit of zapnometinib in patients with severe Covid-19 and supports further evaluation in severe viral diseases. Atriva Therapeutics and investigators will continue to evaluate the RESPIRE data and will provide an update on the full dataset in due course. The POC… Read More

#Covid-19 #News #Trending News

#Antivirals #Monkeypox #Research study

Can a smallpox antiviral be used to treat monkeypox?

A new study has found that the antiviral tecovirimat (TPOXX) appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions. This University of California Davis Health (UC Davis Health) study is one of the earliest studies to assess and report the outcomes of treating patients… Read More

#News #Trending News

#Antivirals #Covid-19 #WHO

WHO recommends Pfzier’s antiviral combo for Covid-19 patients  

The World Health Organisation (WHO) has strongly recommended a combination of antiviral drugs for patients at a high risk of hospital admission due to Covid-19.   The WHO is recommending Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) for patients with non-severe covid-19 who are… Read More

#News

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News

#Antivirals #Covid-19 #Research

How will this anti-viral nasal spray protect against Covid-19? 

Birmingham Biotech and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against Covid-19. The formulation was engineered by Professor Liam Grover, from the university’s Healthcare Technologies Institute, and a team of researchers who also collaborated on its testing.  Covid-19… Read More

#Covid-19 #News

#Antivirals #Biotherapeutics #Covid-19 #Immunology / Virology & Vaccines

Beximco Pharma introduces an oral antiviral drug for Covid-19 treatment 

Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh.   Molnupiravir is world’s first oral product to treat symptomatic Covid-19,… Read More

#Covid-19 #News #Trending News

#Antivirals #Biologics #Biopharmaceuticals #Collaboration #Covid-19 #Laboratory data

This week in drug discovery (1-5 November) 

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent… Read More

#News #Trending News

#Antivirals #Covid-19 #Drug discovery

Covid-19 antiviral pill cuts hospitalisation and deaths in half

If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Antivirals #Cellular & Molecular biology #Drug targets

Sugar-coated viral proteins hijack and hitch a ride out of cells

Researchers from the Universities of Melbourne, York, Warwick and Oxford have shed light on how encapsulated viruses like hepatitis B, dengue and SARS-CoV-2 hijack the protein manufacturing and distribution pathways in the cell. They have also identified a potential broad spectrum anti-viral drug target to stop them in their tracks. Read More

#Editor's Choice #News